Source: FRED HUTCHINSON CANCER CENTER submitted to NRP
SEATTLE DIETARY BIOMARKER DEVELOPMENT CENTER
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
ACTIVE
Funding Source
Reporting Frequency
Annual
Accession No.
1029576
Grant No.
2022-67017-38475
Cumulative Award Amt.
$3,919,947.73
Proposal No.
2022-05089
Multistate No.
(N/A)
Project Start Date
Sep 1, 2022
Project End Date
Aug 31, 2025
Grant Year
2024
Program Code
[A1342]- Food Specific Molecular Profiles and Biomarkers of Food and Nutrient Intake, and Dietary Exposure
Recipient Organization
FRED HUTCHINSON CANCER CENTER
1100 FAIRVIEW AVE N
SEATTLE,WA 981090000
Performing Department
Cancer Prevention Program
Non Technical Summary
The central mission of the Seattle Dietary Biomarker Development Center (DBDC) is to advance the science of measuring complex dietary exposures by rigorous identification and validation of dietary biomarkers that improve upon measurement error prone self-reported diet. This is an important area of research because inconsistent evidence and measurement error in dietary self-report have prevented broad nutrition-focused population interventions and public health policy initiatives from moving forward in a consistent manner. Objective biomarkers of diet using blood and urine measured using metabolomics can help address this important issue. The Seattle Dietary Biomarker Development Center will use two phases of controlled feeding studies for metabolomics discovery of MyPlate foods, food groups and dietary patterns. Blood and urine samples collected during the feeding studies will be assayed using untargeted LC-MS metabolomics for biomarker discovery. In a third study phase, validation of the dietary biomarkers using targeted LC-MS metabolomics and comparison to both benchmark biomarkers and self-reported diet will be accomplished using data and archived biospecimens from three, diverse independent cohorts; the Cancer Prevention Study-3, the Hispanic Community Health Study/Study of Latinos and the Women's Health Initiative. Identification of biomarkers of diet has the potential to improve dietary assessment in the US population and to understand better the relationships between diet and health across the lifespan.
Animal Health Component
40%
Research Effort Categories
Basic
40%
Applied
40%
Developmental
20%
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
70273101010100%
Goals / Objectives
The central mission of the Seattle Dietary Biomarker Development Center (DBDC) is to advance the science of measuring complex dietary exposures by rigorous identification and validation of dietary biomarkers that improve upon measurement error prone self-reported diet. The Seattle DBDC will conduct a three-phase Biomarkers Project (BP) as two controlled feeding studies (Phases 1 and 2) for discovery, followed by a validation study (Phase 3) in independent cohorts. BP Phase 1 is focused on discovery of biomarkers of USDA's MyPlate food groups/subgroup comparisons, their half-lives, and dynamic range. BP Phase 2 is focused on discovery of biomarkers of semi-habitual diet/dietary patterns, and comparison to both dietary self-report and benchmark biomarkers . Laboratory analyses for discovery (Phases 1 and 2) will be conducted with untargeted LC-MS metabolomics of aqueous and lipid molecules in feeding study collected biospecimens. Metabolites meeting discovery criteria will move forward for validation on a targeted LC-MS panel, informed by discovery metabolites from Phases 1 and 2. The validation (BP Phase 3) will utilize archived blood and urine specimens from three diverse cohorts: the American Cancer Society's Cancer Prevention Study-3, the Hispanic Community Health Study/Study of Latinos and the Women's Health Initiative. A Consortium will be comprised of the Seattle DBDC, other Biomarker Centers, a Data Coordinating Center, NIH and USDA-NIFA. The Consortium will guide, integrate and disseminate the research to maximize scientific impact with respect to improving dietary exposure measurement that will be applied to nutrition research and surveillance across the lifespan for health promotion and disease prevention.
Project Methods
The Seattle Dietary Biomarker Development Center (DBDC) will conduct a three-phase Biomarkers Project (BP). The methods, evaluation, milestones and deliverables are described below. The BP is preceded by a planning phasePlanning Phase Objective 1 - Harmonize and Collaborate with Consortium Steering Committee (Yr 1)Establish roles and responsibilities of Seattle DBDC Directors within the Consortium Steering Committee (SC).Develop plans to implement harmonized procedures and methods for: (a) performing metabolomics assays, QC and metabolite identification; (b) comparing biomarker performance with self-reported dietary assessment instruments and other gold standard, benchmark biomarkers; (c) data curation and harmonization; (e) Consortium policies for data sharing, data and safety monitoring, publications and presentations, and other Consortium-generated resources.Deliverables: Harmonized intervention designs and procedures; Consortium SC procedures; workflow for Seattle DBDC-DCC interactions.Planning Phase Objective 2 - BP preparations (Yr 1):Weekly Seattle DBDC Executive Committee (EC) and Core meetings, monthly Seattle DBDC meetings. Confirm roles, responsibilities, communication strategies and both internal and external timelines.Establish fiscal management and tracking systems.Finalize Data and Safety Monitoring Plans (DSMPs) and adverse event reporting procedures.Create cloud-based study database including QA/QC protocols to ensure accurate data collection and creation of common data elements (CDEs).Finalize BP Phase 1 feeding study preparations including clinical protocols, feeding study menus, consent forms, participant recruitment documents, data collection forms and participant questionnaires.Create manual of operations for BP Phase 1, including workflows.Complete training of personnel.Deliverables: Investigator and staff roles and responsibilities, subcontracts executed, protocols, consent forms, data collection forms and all other BP Phase 1 materials, manual of operations, database creation, staff training plan, fiscal systems in place.Planning Phase Objective 3 - Fulfill Regulatory Requirements (Yr 1):Obtain approval of BP protocols by the USDA-NIFA-appointed DSMB.Obtain single-site Fred Hutch IRB submission for BP Phase 1.Obtain Fred Hutch Clinical Research Support (CRS), Prevention Center Shared Resource (PCSR) and Nutrition Assessment Shared Resource (NASR) agreements for BP Phase 1.Obtain Fred Hutch cyber-security approval of cloud-based database.Deliverables: Consortium DSMB approval of Seattle DBDC protocols; Fred Hutch IRB, CRS, PCSR and NASR approvals and agreements.BP Phase 1 Objectives (Yr 1 -Yr 5)Screening, recruitment and retention of participants for Phase 1 feeding study.Collection, processing, tracking and storage of biospecimens.Data entry and QC checking of Phase 1 data, including data on unconsumed Phase 1 study foods.Send Phase 1 biospecimens to Metabolomics Core (MC) at end of Phase 1 for untargeted LC-MS assays; receive results.Perform QC checks on lab blinded duplicates, data cleaning, including merging of lab data with demographic and clinical data into cloud database. Metabolomics Core (MC), Data Analysis Core (DAC), DCC and other Centers work iteratively on biomarker discovery, identification of unknown metabolites and statistical analysis using the completed metabolomics assay data and Phase 1 feeding study data.Deliverables/Milestones for BP Phase 1: Meeting recruitment and retention goals with no more than 14% drop out rate, timely data entry and QC, successful collection and assay of biospecimens, initiate collaborative work on statistical analysis and biomarker identification.BP Phase 2 Objectives (Yr 2- Yr 4).Finalize Phase 2 feeding study materials: clinical protocols, feeding study menus, consent forms, participant recruitment documents, data collection forms (e.g. anthropometry, blood draw forms) and participant questionnaires.Initiate and obtain single-site Fred Hutch IRB submission for Phase 2 feeding study.Initiate and obtain Fred Hutch CRS, PCSR and NASR agreements for Phase 2.Manual of Operations modifications to include Phase 2 protocols.Screening, recruitment and retention of participants for Phase 2.Collection, processing, tracking and storage of biospecimens.Conduct self-reported dietary assessment.Data entry and QC checking of Phase 2 dataSend Phase 2 biospecimens to MC for untargeted LC-MS assaysPerform QC checks on lab blinded duplicates data cleaning, including merging of lab data with demographic and clinical data into cloud database. MC, DAC, DCC and other Centers work iteratively on biomarker discovery, identification of unknown metabolites and statistical analysis using the completed metabolomics assay data and Phase 2 feeding study data and confirmation of any metabolites emerging in both Phase 1 and Phase 2.Develop and test targeted LC-MS panel informed by Phase 1 and 2 results.Work collaboratively with DCC and Consortium on statistical methods for biomarker confirmation for metabolites identified in Phases 1 and 2.Deliverables/Milestones for BP Phase 2; Final protocols, consent forms, data collection forms and management plan, manual of operations, regulatory approvals for Phase 2, meeting recruitment and retention goals with no more than 16% drop out, completion of > 95% of 24hr dietary recalls and 100% of 4-day food records, timely data entry and QC, successful collection and assay of biospecimens, continuing collaborative work on biomarker identification and statistical analysis.BP Phase 3 Objectives (Yr 2 - Yr 4).Establish Phase 3 protocol and workflows.Obtain Fred Hutch IRB submission for Phase 3Modify database for new data elements from the validation cohorts.Set up and execute material transfer agreements (MTA) and data use agreements (DUA) with the three validation cohorts (CPS-3, HCHS/SOL, WHI) and with the DCC.Receive de-identified biospecimens from CPS-3, HCHS/SOL and WHI, log and track aliquots and send to MC.Receive de-identified archived study data (self-reported diet, participant characteristics) from CPS-3, HCHS/SOL and WHI. Conduct data cleaning, check for missing data, perform data harmonization as needed.Perform QC checks on lab blinded duplicates data cleaning, including merging of lab data with demographic, dietary and other data into cloud database.Send Phase 2 biospecimens for benchmark biomarkers to University of WA Core Lab.MC, DAC, DCC and other Centers work iteratively on biomarker validation, identification of unknown metabolites and statistical analysis using the completed metabolomics validation assay data, benchmark biomarkers and dietary self-report and Phase 3.Deliverables/Milestones for BP Phase 3: Successful transfer of biospecimens and data from independent cohorts, completion of laboratory assays and return of data, completion of data cleaning and harmonization, continuing collaborative work on biomarker validation, identification unknown metabolites and statistical analysis.BP completion (Year 5).?Complete remaining laboratory assays, including repeats due to QC issues or technical issues with equipment.Upload lab results to database, perform QC checks.Complete statistical analyses planned by the DAC and DCC.Upload datasets, data dictionary and all data documentation (including analysis code) to the DCC.Write and submit manuscriptsFinal report to USDA-NIFA .Final Deliverable/Milestones: Completion of data analysis, planned manuscripts, and data transfer to DCC. Finalize regulatory requirements.

Progress 09/01/24 to 08/31/25

Outputs
Target Audience: Nothing Reported Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided? Nothing Reported How have the results been disseminated to communities of interest?The DBDC Steering Committee organized a symposium session for the 2023 American Society for Nutrition (ASN) Annual Meeting entitled "Paving the Way to Precision Nutrition: Using Metabolomics to Discover & Validate Dietary Biomarkers" (July 23, 2023). Dr. Lampe chaired the session and Dr. Neuhouser presented on the Seattle DBDC activities. Additionally, Dr. Raftery, with Drs. Fiehn and Clish from the other DBDC centers, organized the workshop "Nutritional Metabolomics - Biomarkers of Dietary Intake and Exposure," at Metabolomics 2024, the 20th Annual Conference of the Metabolomics Society held June 2024 in Osaka, Japan. The workshop showcased our scientific progress with this project. Seattle DBDC members, Drs. Neuhouser, Lampe, McCullough, and Wang organized and presented a symposium session, "Applications of Metabolomics in Diet Assessment and Analysis," at the International Conference on Diet and Activity Methods in Toronto, Canada (April 29, 2025), which outlined the application of metabolomics biomarkers and DBDC activities. Additionally, April 5, 2025 was the online publication (ahead of print) of our collaboration article with the consortium, The Dietary Biomarkers Development Consortium: An Initiative for Discovery and Validation of Dietary Biomarkers for Precision Nutrition published by Current Developments in Nutrition. https://doi.org/10.1016/j.cdnut.2025.107435. What do you plan to do during the next reporting period to accomplish the goals?We will complete all participant based activities of Phase 2 and complete metabolomics analysis on the study samples (blood and urine).We will finalize data analysis and interpretation for Phase 1. We will start data analysis and interpretation for Phase 2. For Phase 3, we will coordinate sample transfer as outlined in the proposal and start metabolomics analysis. We will continue to be active members of the national consortium.We will complete all other planned activities for the project including drafting and submitting manuscripts.

Impacts
What was accomplished under these goals? Our Phase 1 was divided into two feeding trials, the first one tested beef and pinto beans; the second tested eggs and black beans for both pharmacokinetic and dose-response testing. In February 2023 we started recruitment and enrollment into the meat and pinto beans trial. We randomized 20 participants into this trial and completed measures from15 participants as planned. In March 2024, we started recruitment and enrollment into the second feeding trial, testing eggs and black beans. We randomized 18 participants and completed measures from15 participants as planned. As with any feeding trial, we did have participants drop-out or who were subject to investigator-initiated withdrawal (n=8) for various reasons including the time commitment required and the difficulty of staying just on the study foods. We recruited study volunteers by placing advertisements, distributing flyers throughout the community and local institutions of higher education, and social media. The exclusion criteria addressed a mix of medical and practical issues and were agreed upon by the DIWG and the Data Safety and Monitoring Board (DSMB). Our recruitment efforts have been successful in getting interest in the study objectives with 180 persons filling out the RedCap screening questionnaire (available via our study website). In Phase 2, participants attend a total of 10 study visits at the Fred Hutch Prevention Center Clinic: an orientation visit, at which time participants will provide consent, have height, weight and blood pressure measured, complete a questionnaire and are provided with a urine and stool home-collection kit (and instructions), a Food Frequency Questionnaire (FFQ), and a 4-day food record; an eligibility confirmation visit where participants will return the FFQ and food record, urine and stool specimens, and give a fasting blood sample to confirmation eligibility (eligible participants will be randomized to feeding period; ineligible participants will be withdrawn from the study); a study visit to pick up study meals (both periods); a visit to complete a fasting blood draw, deliver urine collected at home and measure weight (both periods); a mid-point visit to complete a fasting blood draw and measure weight (both periods); and a final visit to complete a fasting blood draw and to deliver urine and stool specimens collected at home (both periods). As with Phase 1, the Phase 2 eligibility criteria were approved by the DIWG and the DSMB. The collected biospecimens will be used for study outcomes and archived for future studies. Healthy volunteers will be recruited for this study. Healthy volunteers are well-suited for this study so results will be generalizable. We started recruitment for Phase 2 in March 2025 and have randomized 8 participants to date. We are confident that we will be able to complete the 35 participants as planned within the next 6-8 months. We are also actively working on Phase 3 as per the original timeline of the study. All transfer agreements have been secured and samples are in the process of being compiled and shipped for metabolomics testing at NW-MRC. Collaborative Consortium Activities: TheSeattle Dietary Biomarker Development Center (DBDC) has been an active member of the national consortium created by NIH/NIDDK and USDA-NIFA. In Year 01, PD/PI Dr. Marian Neuhouser was named Chair of the Consortium Steering Committee, Dr. Lampe (mPI) was named Co-Chair of the Dietary Intervention Working Group (DIWG) and Dr. Shojaie (Co-I) was named Co-Chair of the Data Analysis/Data Harmonization Working Group. Dr. Dan Raftery was chair of the Metabolomics Working Group in Year 2. Dr. Schenk has been part of the Project Managers and Consortium Paper Working Groups. All other investigators have been active in the established and on-going discussions of the Consortium Working Groups and the Steering Committee. Drs. Sandi Navarro and Wentao Zhu have been working as part of an ongoing consortium effort to compile a Global Compound Summary using a literature review of metabolomics of food-related biomarkers. To date, they have identified 35 publications yielding candidate biomarkers for the 4 Phase 1 study foods. The Seattle DBDC organized and hosted the in-person DBDC Steering Committee on the Fred Hutch Cancer Center campus on May 29, 2024.

Publications

  • Type: Other Journal Articles Status: Awaiting Publication Year Published: 2025 Citation: Hrishikesh Chakraborty, Qi Sun, Shilpa N Bhupathiraju, Jeannette M Schenk, Darya O Mishchuk, James R Bain, Xuan He, Jianghao Sun, James Harnly, William Simmons, Daniel Raftery, Liming Liang, John W Newman, Oliver Fiehn, Clary B Clish, Johanna W Lampe, Brian J Bennett, Sandi L Navarro, Ying Wang, Cheng Zheng, Yasmin Mossavar-Rahmani, Marjorie L McCullough, Ying Huang, Ali Shojaie, Wentao Zhu, Danijel Djukovic, Frank Sacks, Jonathan Williams, Francene M Steinberg, Sean H Adams, Frank B Hu, Marian L Neuhouser, Carolyn M Slupsky, Padma Maruvada, The Dietary Biomarkers Development Consortium: An Initiative for Discovery and Validation of Dietary Biomarkers for Precision Nutrition, Current Developments in Nutrition, Volume 9, Issue 5, 2025


Progress 09/01/23 to 08/31/24

Outputs
Target Audience: Nothing Reported Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided? Nothing Reported How have the results been disseminated to communities of interest? Nothing Reported What do you plan to do during the next reporting period to accomplish the goals?We will complete all participant based activities of Phase 1 and conduct metabolomics analysis on the study samples (blood and urine), including those from the pharmacokinetics study. We will conduct data analysis and interpretation for Phase 1. We will conduct the feeding trial for Phase 2. For Phase 3, we will finalize DUAs and MTAs and coordinate sample transfer as outlined in the proposal. We will continue to be active members of the national consortium.

Impacts
What was accomplished under these goals? Our Phase 1 is divided into two feeding trials, the first one tests beef and pinto beans; the second tests eggs and black beans. On February 5, 2023 we started recruitment and enrollment into the meat and pinto beans trial. The aim of this feeding trial is to have 15 participants complete all measures for each feeding trial. As of May 1, 2024 we had randomized 20 participants into this trial, 14 participants completed all feeding periods and the last participant is currently on study. We have also recently started recruitment into the second feeding trial, testing eggs and black beans. We have randomized 8 participants into this trial with 3 participants having completed at least one of the three feeding periods. As with any feeding trial we did have participants drop-out or who were subject to investigator initiated withdrawl (n=7) for various reasons including the time commitment required and the difficulty of staying just on the study foods.We are well positioned to complete this second trial in Phase 1 within the next 4-6 months. We have pulled and appropriately batched samples to start metabolomics analysis. We have finalized Phase 2 design in coordination with all other members of the Consortium, obtained DSMB and IRB approvals. We started menu development and all other operational logistics to be able to start recruitment into Phase 2 at the beginning of the new grant year. We have also commenced planning and design for Phase 3 as per the original timeline of the study. We are working closely with the entities that will be providing samples and have initiated the process of data and sample transfer agreements. We continued being active members of the national consortium created by NIH and USDA-NIFA.Dr. Daniel Raftery served as chair of the Metabolomics Working Group in Year 2. The DBDC Steering Committee organized a symposium session for the 2023 American Society for Nutrition (ASN) Annual Meeting entitled "Paving the Way to Precision Nutrition: Using Metabolomics to Discover & Validate Dietary Biomarkers" (July 23, 2023). Dr. Lampe chaired the session and Dr. Neuhouser presented on the Seattle DBDC activities. Drs. Sandi Navarro and Wentao Zhu have been working on a consortium effort to compile a comprehensive literature review of metabolomics of food related biomarkers. Additionally, Dr. Raftery, with Drs. Fiehn and Clish from the other DBDC centers, are organizing a workshop "Nutritional Metabolomics - Biomarkers of Dietary Intake and Exposure," for Metabolomics 2024, the 20th Annual Conference of the Metabolomics Society being held June 2024 in Osaka, Japan. The workshop will showcase and discuss our scientific progress with this project.

Publications


    Progress 09/01/22 to 08/31/23

    Outputs
    Target Audience: Nothing Reported Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided? Nothing Reported How have the results been disseminated to communities of interest? Nothing Reported What do you plan to do during the next reporting period to accomplish the goals?We will continue to be active members of the national consortium. We will continue Phase 1 activities and we expect to complete Phase 1, including the second trial testing eggs and black beans during the next reporting period including metabolomics analysis for Phase 1. In the next 6 months, we will also finalize the design for Phase 2, obtain DSMB and IRB approval for Phase 2 and begin Phase 2 recruitment and other operational activities.

    Impacts
    What was accomplished under these goals? TheSeattle Dietary Biomarker Development Center (DBDC) has been an active member of the national consortium created by NIH and USDA-NIFA. PD/PI Dr. Marian Neuhouser was named Chair of the Consortium Steering Committee, Dr. Lampe (mPI) was named Co-Chair of the Dietary Intervention Working Group and Dr. Shojaie (Co-I) was named Co-Chair of the Data Analysis/Data Harmonization Working Group. All other Investigators have been active in the established and on-going discussions of the Consortium Working Groups. The Seattle investigators meet monthly. As per plan, we completed design of all aspects of the Phase 1 feeding study in coordination with the national consortium. All materials were approved by IRB. Our Phase 1 is divided into two feeding trials, the first one tests beef and pinto beans; the second tests eggs and black beans. On February 5, 2023 we started recruitment and enrollment into the meat and pinto beans trial. As of May 21, 2023 we have had 45 persons access the RedCap screening questionnaire (available via our study website). Seven were incomplete questionnaires. Of the 38 who completed, 16 (42.1.5%) were not eligible due to study exclusion criteria or did not confirm eligibility information requests, and an additional 9 did not respond to requests to attend an orientation session. Of the 13 eligible and interested, so far 7 have completed the orientation and consent session, at which time 2 were deemed ineligible based on baseline measures (blood pressure and blood tests). Four participants have been randomized into the study, with one participant finishing all measures in the coming week. By the end of August 2023, we expect to have had 5 participants completed the first trial testing beef and pinto beans (recruitment goal is 15 participants per Phase 1 trial completing all feeding study requirements).

    Publications